EARTH CITY, Mo.–(BUSINESS WIRE)–Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin™ (paromomycin sulfate) exclusively through Humatin Total Care.
This patient-first drug management program optimizes the benefits of Humatin for patients with acute and chronic intestinal amebiasis, a parasitic infection of the intestines caused by the protozoan E. histolytica. According to the most recent report, among patients with amebiasis in the United States 33% were Hispanic immigrants and 17% were Asia or the Pacific Islands immigrants.
“Our dedicated Humatin Total Care coordinator works with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery for the patient.”
“Of those infected, approximately 10-20% become sick with symptoms that include loose stool, stomach pain and abdominal cramping, which usually develop within 2-4 weeks and are generally mild,” says Donovan Quill, president and CEO, Optime Care. “Optime Care’s patient-first approach can ensure care continuity across the entire patient journey with robust communication to yield rich data that clinicians can use to make more informed decisions and improve the overall patient experience.”
It is estimated that 14 of every 1,000 returning travelers with diarrhea have amebiasis, which accounts for 12.5% of all microbiologically confirmed cases.
Quill adds, “Our dedicated Humatin Total Care coordinator works with insurance companies to verify coverage and reimbursement benefits, provide access to financial assistance and arrange drug delivery for the patient.”
